ClinicalTrials.gg
Status unknownNCT04849325GENIUSUpdated Mar 17, 2022

IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease

An interventional study of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™) and Percutaneous Transluminal Angioplasty (PTA) Device in Critical Limb Ischemia (CLI), sponsored by Biotyx Medical (Shenzhen) Co., Ltd.. Status unknown at 29 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-03-17.

Sponsored by Biotyx Medical (Shenzhen) Co., Ltd. (part of LifeTech Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Chronic Limb-Threatening Ischemia with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · China.

Planned enrollment
8th of 15
120 · median 120
Started
2021
with 1 other
No phase
2 of 23
none open now
Registered
12th of 23
by date
Lead sponsor
1 of 23
Biotyx Medical (Shenzhen) Co., Ltd.

Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in China, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 with no phase, and was the 12th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

7 of the 23 studies in Chronic Limb-Threatening Ischemia with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Chronic Limb-Threatening Ischemia with a site in China, or all of them as a file.
02

Study summary

A prospective, multi-center, randomized trial to assess the safety and effectiveness of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™) in treating patients with infrapopliteal arterial stenosis or occlusive disease.

03

Conditions studied

  • Critical Limb Ischemia (CLI)
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must between 18 and 85 years old, without gender limit.
  2. Patients who can understand the purpose of the trial, voluntarily participate in and sign the form, and complete the 1-year follow-up.
  3. Subject has lower extremity atherosclerotic occlusive disease with symptomatic Critical Limb Ischemia (CLI).
  4. Rutherford Becker Clinical Category 3-5.
  5. The target lesion is below the popliteal artery (including bifurcation).
  6. The target lesion is located in the proximal 2/3 of native infrapopliteal vessels or tibiofibular trunk.
  7. The target lesion stenosis is ≥70% or occlusion of no more than two infrapopliteal arteries (including the anterior and/or posterior tibial and/or peroneal artery and/or tibiofibular trunk).
  8. The length of target lesion is ≤200mm, which could be covered by no more than two stents, with vessel diameter of 2.25-4.25 mm.

Exclusion criteria

Exclusion Criteria:

  1. Severe renal insufficiency, hepatic dysfunction (Cr>2 times of normal limit or renal dialysis, or AST > 5 times of normal limit).
  2. Surgery in target vessel before treatment.
  3. Volume reduction surgery in target vessel before treatment.
  4. Thrombosis in target vessel, or acute thrombosis requiring thrombolysis and thrombectomy.
  5. Systematic coagulation disorder or hypercoagulability.
  6. Lower extremity arteries surgery or thrombolytic therapy in the ipsilateral extremity in the past 6 weeks.
  7. Stroke occurs within 3 months before surgery, or stroke occurs with severe hemiplegia aphasia sequelae more than 3 months before treatment.
  8. Acute myocardial infarction or angina pectoris within 30 days before treatment.
  9. In-stent restenosis.
  10. Guide wire cannot pass target lesion.
  11. Previously treated with drug eluting balloon within 1 year before treatment.
  12. More than two infrapopliteal arteries needed treatment.
  13. The inflow tract (including ipsilateral iliac artery, femoral artery, popliteal artery) has lumen stenosis >30% with or without intervention.
  14. The inflow tract (including ipsilateral iliac artery, femoral artery, popliteal artery) has > 150 mm stenosis or occlusion before treatment.
  15. Aneurysm of lower extremity artery.
  16. Thromboangiitis obliterans (Buerger's disease).
  17. Significant (≥ 50% stenosis) lesion in a distal outflow artery that would be perfused by the target vessel and that requires treatment at the time of the index procedure.
  18. Patients known to be allergic to aspirin, heparin, Plavix, contrast agents, Sirolimus, poly lactic acid polymer, iron, zinc and their degradation product, and those who cannot tolerate postoperative dual anti- therapy.
  19. Patients who have a history of disease related to iron overload or iron disorder, such as hereditary hemochromatosis, etc.
  20. Patients who are participating in another clinical trial that has not yet completed its primary endpoint.
  21. Pregnant or those who plan pregnancy during the clinical investigation follow-up period.
  22. Angiography suggests intraoperative thromboendarterectomy, percutaneous transluminal rotational atherectomy or laser therapy are needed.
  23. Patients have ≤ 1 year.
  24. Patients who are not suitable for participating the trial judged by investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    IBS Titan

    Device: Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)

  • Active comparator
    Percutaneous Transluminal Angioplasty (PTA)

    Device: Percutaneous Transluminal Angioplasty (PTA) Device

Interventions

  • DeviceSirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)

    Subjects in this arm will be treated with IBS Titan™.

  • DevicePercutaneous Transluminal Angioplasty (PTA) Device

    Subjects in this arm will be treated with PTA device.

06

What researchers measure

Primary outcomes

  1. Primary Patency Rate

    Defined as freedom from total occlusion of target lesion and clinically driven target lesion revascularization (CD-TLR) of target lesion, and freedom from major amputation.

    Time frame: 180 days

Secondary outcomes

  1. All-cause mortality

    Time frame: 30 days, 180 days, 365 days

  2. Incidence of Clinically-driven Target Vessel Revascularization (CD-TLR)

    CD-TLR is defined as any TLR of target lesions associated with Rutherford category exacerbation and/or increasing in the size of preexisting wounds and/or the occurrence of new wounds.

    Time frame: 30 days, 180 days, 365 days

  3. Incidence of major amputation

    Unplanned amputation of the lower limb above the ankle on the target lesion side

    Time frame: 30 days, 180 days, 365 days

  4. Rate of Device Success

    Device success is defined on a per device basis, as the achievement of successful delivery, deployment of stent at the intended infrapopliteal target site(s) and successful withdrawal of the delivery catheter.

    Time frame: Immediately after the procedure

  5. Rate of Participants with Technical Success

    Defined as restoration of blood flow in the target vessel and angiogram indicates the residual stenosis \<50%.

    Time frame: Immediately after the procedure

  6. Rate of Participants with Procedural Success

    Defined as the combination of technical success, device success, and absence of procedural complications.

    Time frame: Immediately after the procedure

  7. Late Lumen Loss

    Time frame: 180 days

  8. Incidence of Target lesion restenosis

    Defined as a reduction in the luminal diameter \>50% by angiography or CTA within the treated lesion plus the 5-mm segments proximal and distal to it or, as a peak systolic velocity ratio (PSVR) \>2.4 by DUS. Note 1: Doppler ultrasound will be performed at 30 days and 365 days, DSA angiography will be performed 180 days. Note 2: If the patient presented with CD-TLR in advance, i.e. the patient reached the endpoint in advance, the restenosis before reintervention was assessed.

    Time frame: 30 days, 180 days, 365 days

  9. Change in ankle-brachial index (ABI) compared to baseline (before treatment)

    Time frame: 30 days, 180 days, 365 days

  10. Change in Rutherford-Becker category compared to baseline (before treatment)

    Categories and Clinical Description (higher scores mean a worse outcome): Category 0 = Asymptomatic, no hemodynamically significant occlusive disease, Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication, Category 4 = Ischemic rest pain, Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable.

    Time frame: 30 days, 180 days, 365 days

  11. Wound healing rate of ulcer patients

    Time frame: 30 days, 180 days, 365 days

07

Study locations

14 of 29 sites recruiting
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, China
    Not yet recruiting
    • Zhong Chen · Principal investigator
  • Beijing Hospital
    Beijing, China
    Not yet recruiting
    • Yongjun Li · Principal investigator
  • Beijing Tsinghua Changgung Hospital
    Beijing, China
    Not yet recruiting
    • Weiwei Wu · Principal investigator
  • Peking Union Medical College Hospital
    Beijing, China
    Not yet recruiting
    • Yuehong Zheng · Principal investigator
  • Peking University First Hospital
    Beijing, China
    Not yet recruiting
    • Yinghua Zou · Principal investigator
  • Peking University People's Hospital
    Beijing, China
    Recruiting
    • Xiaoming Zhang · Principal investigator
  • Peking University Third Hospital
    Beijing, China
    Recruiting
    • Xuan Li · Principal investigator
  • People's Liberation Army General Hospital
    Beijing, China
    Recruiting
    • Wei Guo · Principal investigator
  • Xiyuan Hospital, China Academy of Chinese Medical Sciences
    Beijing, China
    Not yet recruiting
    • Baixi Zhuang · Principal investigator
  • Xuanwu Hospital, Capital Medical University
    Beijing, China
    Recruiting
    • Lianrui Guo · Principal investigator
  • The First People's Hospital of Changzhou
    Changzhou, China
    Recruiting
    • Yunfeng Zhu · Principal investigator
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
    Recruiting
    • Yu Zhao · Principal investigator
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, China
    Not yet recruiting
    • Feng Wang · Principal investigator
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, China
    Recruiting
    • Pingfan Guo · Principal investigator
  • The First Affiliated Hospital of Guangxi Medical University
    Guangxi, China
    Not yet recruiting
    • Xiao Qin · Principal investigator
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, China
    Not yet recruiting
    • Hongkun Zhang · Principal investigator
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, China
    Not yet recruiting
    • Weimin Zhou · Principal investigator
  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
    Nanjing, China
    Not yet recruiting
    • Xiaoqiang Li · Principal investigator
  • The First Affiliated Hospital with Nanjing Medical University
    Nanjing, China
    Not yet recruiting
    • Xiwei Zhang · Principal investigator
  • Renji Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, China
    Not yet recruiting
    • Lan Zhang · Principal investigator
  • Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, China
    Recruiting
    • Xinwu Lu · Principal investigator
  • Zhongshan Hospital, Fudan University
    Shanghai, China
    Not yet recruiting
    • Weiguo Fu · Principal investigator
  • Shengjing Hospital of China Medical University
    Shenyang, China
    Recruiting
    • Zhaoyu Liu · Principal investigator
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, China
    Not yet recruiting
    • Wei Bi · Principal investigator
  • Second Hospital of Shanxi Medical University
    Taiyuan, China
    Recruiting
    • Honglin Dong · Principal investigator
  • General Hospital of Tianjin Medical University
    Tianjin, China
    Recruiting
    • Xiangchen Dai · Principal investigator
  • Tianjin 4th Centre Hospital
    Tianjin, China
    Recruiting
    • Yidong Liu · Principal investigator
  • Henan Provincial People's Hospital
    Zhengzhou, China
    Recruiting
    • Shuiting Zhai · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
    Recruiting
    • Zhen Li · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Apr 2024, 28 months after the start.

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2021
First posted
Apr 19, 2021
StartActual
Dec 9, 2021
Primary completionEst.
Apr 2024
CompletionEst.
Oct 2024
Last update
Mar 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04849325
Responsible party
Sponsor
First posted
Apr 19, 2021
Start date
Dec 9, 2021
Primary completion
Apr 2024 (estimated)
Completion
Oct 2024 (estimated)
Last update
Mar 17, 2022

Study contacts

Ying Xia
Contact
xiaying@lifetechmed.com
86 13760184511

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion